<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212379</url>
  </required_header>
  <id_info>
    <org_study_id>2014-000828-24</org_study_id>
    <secondary_id>ANRS 163 ETRAL</secondary_id>
    <nct_id>NCT02212379</nct_id>
  </id_info>
  <brief_title>Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL</brief_title>
  <official_title>A Non-comparative Phase II Trial Evaluating the Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age With an HIV-RNA Plasma Viremia Below 50 Copies/mL Under a Current Boosted Protease Inhibitor Containing Regimen (ANRS 163 ETRAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, international, non randomized (single arm), open, phase II trial aims to
      evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological
      success in virologically suppressed HIV-1 infected patients, of at least 45 years of age,
      switching from a boosted PI-containing regimen. Patients will be followed for 96 weeks.
      Measurement of primary endpoint will be at 48 weeks. Virological success is defined as the
      absence of 2 consecutive plasma viral load &gt;50 copies/mL within 2 to 4 weeks of a dual
      raltegravir/etravirin regimen. Raltegravir/etravirine will be considered acceptable if the
      percentage of patients in virological success at week 48 is significantly above 90 %.
      Assuming a 95 % virological success rate, by including 160 individuals and considering the
      strategy to be acceptable if no more than 8 individuals have virological failure;
      investigators will have a 95 % probability to discard a combination for which efficacy is
      smaller than 90 % and investigators will select with a power of 80 % the strategy for which
      the efficacy is above or equal to 95 %. The principal secondary endpoint is the proportion of
      patients in therapeutic success up to week 48 and 96.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the capacity to maintain virological success in HIV-1 infected patients, of at least 45 years of age, with suppressed plasma viremia switching from a boosted PI-containing regimen.</measure>
    <time_frame>week 48</time_frame>
    <description>Virological success is defined as the absence of 2 consecutive plasma viral loads (VL) &gt; 50 copies/mL within 2 to 4 weeks of a dual raltegravir/etravirine regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>From day 0 to week 48 and week 96</time_frame>
    <description>Incidence of clinical and biological adverse effects
Incidence of clinical and biological adverse events (grade 3 or 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seminal sub-study</measure>
    <time_frame>week 48</time_frame>
    <description>• Assessment of HIV-RNA viral load and Cmin (Minimal Drug Concentration) of raltegravir and etravirine in human male genital compartment (20 patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological outcome</measure>
    <time_frame>at each time point from day 0</time_frame>
    <description>- Evolution of CD4+, CD8+ T cells counts and CD4/CD8 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of cardiovascular risk</measure>
    <time_frame>from day 0 to week 48 and week 96</time_frame>
    <description>• Evolution of the calibrated Framingham risk score and of the SCORE risk equation including HDL (High Density Lipoprotein) cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of renal function</measure>
    <time_frame>from day 0 to week 96</time_frame>
    <description>• Evolution of renal function evaluated using proteinuria and the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Calculator) formula to estimate the Glomerular Filtration Rate (GFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related, quality of life</measure>
    <time_frame>from day 0 to week 48 and week 96</time_frame>
    <description>• Evaluation of health-related quality of life with a self-assessment questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic parameters</measure>
    <time_frame>from day 0 to week 48 and week 96</time_frame>
    <description>• Evolution of metabolic parameters (fasting triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol and fasting glycemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study: evolution of peripheral and central body fat distribution</measure>
    <time_frame>from day 0 to week 48 and week 96</time_frame>
    <description>• Evolution of limb lean, limb fat, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), measured by DXA scan (Dual-energy X-Ray Absorptiometry), from D0 to W48 and W96 (DXA scan sub-study, 80 patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>at week-6/ week -4, week 48, and week 96</time_frame>
    <description>• Evaluation of the compliance with a self-assessment questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological success</measure>
    <time_frame>from day 0 to week 48 and week 96</time_frame>
    <description>percentage of patients remaining in therapeutic success
percentage of patients in virological success (plasma HIV-RNA &lt;=50 cp/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment interruption</measure>
    <time_frame>from day 0 to week 96</time_frame>
    <description>• Percentage of patients with trial treatment interruption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure</measure>
    <time_frame>from day 0 to week 96</time_frame>
    <description>• Percentage of patients with plasma HIV-RNA viral load between 51 and 200 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure</measure>
    <time_frame>at time of virological failure</time_frame>
    <description>• Percentage of patients with plasma HIV-RNA VL ˃ 200 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure</measure>
    <time_frame>between day 0 and week 96</time_frame>
    <description>• Median time of virological failure (time limit between the date of the study treatment initiation and the date of virological failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure: resistance mutations</measure>
    <time_frame>between day 0 and week 96</time_frame>
    <description>Percentage of patients with RAL and/or ETR resistance mutations in case of virological failure
Percentage of patients with resistant viruses to all study drug's class in case of virological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure: associated factors</measure>
    <time_frame>between day 0 and week 96</time_frame>
    <description>• Factors associated with the occurrence of plasma HIV-RNA viral load &gt; 50 copies/mL (genotype history, pre-cART viral load, plasma drug concentration (etravirine, raltegravir) at the virological rebound, viral reservoir measured by HIV-DNA at day 0 and adherence assessed with a self-questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total HIV-DNA</measure>
    <time_frame>from day 0 to week 48 and week 96</time_frame>
    <description>• Evolution of total cell-associated HIV-DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameters</measure>
    <time_frame>from day 0 to week 48, and week 96</time_frame>
    <description>• Evolution of the inflammation markers (IL-6hs, sCD14, sCD163, D-Dimers, IP-10, IgG, CRPus and insulin) on frozen plasma aliquots</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study: bone mineral density</measure>
    <time_frame>from day 0, to week 48 and week 96</time_frame>
    <description>• Evolution of bone mineral density measured by DXA scans (DXA scan sub-study, 80 patients)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>raltegravir and etravirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir and etravirine</intervention_name>
    <description>Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.
Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal.</description>
    <arm_group_label>raltegravir and etravirine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  Age ≥ 45 years

          -  Naïve to integrase inhibitor and etravirine

          -  At least 6 months of stable antiretroviral therapy (ART) including a boosted protease
             inhibitor, whatever the number of combined drugs

          -  HIV-RNA plasma VL ≤ 50 copies/mL during the last 24 months prior to screening visit
             (Week-6/Week-4), documented by at least 4 time-points with no more than one blip in
             HIV-RNA plasma viral load between 51 and 200 copies/mL

          -  HIV-RNA plasma VL ≤ 50 copies/mL at screening visit (Week-6/Week-4)

          -  A genotype is available (on amplified DNA at Week-6/Week-4 Visit and/or on RNA in the
             medical history of the patient) and shows a virus sensitive to ETR OR no genotype is
             available (amplification failure on DNA at Week-6/Week-4 Visit and no genotype in the
             medical history of the patient), there are no virological failure on NNRTI in the
             medical history

          -  CD4+ lymphocytes &gt; 200 cells/mm3

          -  Creatinine &lt; 2.5 x ULN

          -  CPK (Creatine Phospho Kinase) &lt; 6 ULN (Upper Limit of Normal)

          -  AST (Aspartate Aminotransferase), ALT (Alanine Aminotransferase) &lt; 5 ULN

          -  Hemoglobin &gt; 10 g/dL

          -  Platelets &gt; 100 000/mm3

          -  Negative urinary pregnancy test and use of efficient contraception for women of
             childbearing potential

          -  For French participants only: subject enrolled in or a beneficiary of a Social
             Security programme (State Medical Aid or AME is not a Social Security programme),
             article L1121-11 of the Public heatlh code

          -  Patients with a coverage from a social health

          -  Signed informed consent

        Exclusion Criteria:

          -  Previous exposure to raltegravir or etravirine

          -  Presence of any documented integrase inhibitor mutation on DNA genotype at
             Week-6/Week-4 and/or on RNA in the medical history of the patient

          -  Positive hepatitis B HBsAg or Positive HBc Ac and negative HBs Ac

          -  HIV-2 infection

          -  Active viral hepatitis C requiring a specific treatment during the 24 months of the
             trial

          -  Patient with a history of non-compliance or irregular follow-up

          -  Initiation of a concomitant anti-hypercholesterolemia (e.g. statins) or antidiabetic
             treatment within the last 3 months prior the screening visit (Week-6 /Week-4)

          -  Patient using: Clopidogrel (Plavix®), Prasugrel (Effient®), Ticagrelor (Brilinta®),
             Ticlopidine (Ticlid®), Flurbiprofen (Antadys® - Cebutid®), Rifampin (Rifampicin® -
             Rifadin® - RofactMC - Rifater®), Rifapentine (Priftin®), St John's wort, Carbamazepine
             (Tegretol®), Phenobarbital, Phenytoin (Dilantin®),Avanafil (Stendra™), Triazolam
             (Halcion®)

          -  Concomitant treatment using interferon, interleukins or any other immunetherapy or
             chemotherapy

          -  Concomitant prophylactic or curative treatment for an opportunistic infection

          -  All conditions (use of alcohol, drugs, etc.) judged by the investigator to possibly
             interfere with trial protocol compliance, adherence and/or trial treatment tolerance

          -  Subjects under &quot;sauvegarde de justice&quot; (judicial protection due to temporarily and
             slightly diminished mental or physical faculties), or under legal guardianship

          -  Subjects participating in another clinical trial evaluating different therapies and
             including an exclusion period that is still in force during the screening phase

          -  Pregnant women or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Katlama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service des Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitié-Salpêtrière, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Reynes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Département des Maladies Infectieuses et Tropicales Hôpital Gui de Chauliac, CHU de Montpellier France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Costagliola, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inserm UMR S 1136 Université Pierre et Marie Curie Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08000</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la santa Creu i San Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr/</url>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>Etravirine</keyword>
  <keyword>aged, 45 and over</keyword>
  <keyword>Viral load</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

